-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, RHWF1oRIcGVpCP+pkle/8l70VuQvjyNBggoyxqEkMU96wuhUo+wNUrd1MuS8ncyr V/miZ/NvI9cygkQxyRn7GA== 0001104659-05-059525.txt : 20051207 0001104659-05-059525.hdr.sgml : 20051207 20051207124727 ACCESSION NUMBER: 0001104659-05-059525 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20051207 DATE AS OF CHANGE: 20051207 GROUP MEMBERS: AVENTIS HOLDINGS INC. GROUP MEMBERS: AVENTIS INC. GROUP MEMBERS: AVENTIS PHARMACEUTICALS INC. GROUP MEMBERS: SANOFI-AVENTIS SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: VIROPHARMA INC CENTRAL INDEX KEY: 0000946840 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 232789550 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-48239 FILM NUMBER: 051249025 BUSINESS ADDRESS: STREET 1: 397 EAGLEVIEW BLVD CITY: EXTON STATE: PA ZIP: 19341 BUSINESS PHONE: 6104587300 MAIL ADDRESS: STREET 1: 397 EAGLEVIEW BOULEVARD CITY: EXTON STATE: PA ZIP: 19341 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: AVENTIS INC CENTRAL INDEX KEY: 0000217028 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 231699163 STATE OF INCORPORATION: PA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 300 SOMERSET CORPORATE BLVD. CITY: BRIDGEWATER STATE: NJ ZIP: 08807 BUSINESS PHONE: (908) 243-6000 MAIL ADDRESS: STREET 1: 300 SOMERSET CORPORATE BLVD. CITY: BRIDGEWATER STATE: NJ ZIP: 08807 FORMER COMPANY: FORMER CONFORMED NAME: RHONE POULENC RORER INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: RORER GROUP INC DATE OF NAME CHANGE: 19900731 FORMER COMPANY: FORMER CONFORMED NAME: RORER AMCHEM INC DATE OF NAME CHANGE: 19770604 SC 13G/A 1 a05-21260_1sc13ga.htm AMENDMENT

 

 

UNITED STATES

 

 

SECURITIES AND EXCHANGE COMMISSION

 

 

Washington, D.C. 20549

 

 

 

 

 

SCHEDULE 13G

 

 

Under the Securities Exchange Act of 1934
(Amendment No. 3)*

 

ViroPharma Incorporated

(Name of Issuer)

COMMON STOCK, $.002 PAR VALUE

(Title of Class of Securities)

928241108

(CUSIP Number)

November 10, 2005

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

o

Rule 13d-1(b)

o

Rule 13d-1(c)

ý

Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 


 

 

CUSIP No. 

 

 

1.

Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
Sanofi-Aventis
Not applicable

 

 

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

 

(a)

o

 

 

(b)

o

 

 

3.

SEC Use Only

 

 

4.

Citizenship or Place of Organization
The Republic of France

 

 

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5.

Sole Voting Power
0 shares

 

6.

Shared Voting Power 
0 shares

 

7.

Sole Dispositive Power 
0 shares

 

8.

Shared Dispositive Power
0 shares

 

 

9.

Aggregate Amount Beneficially Owned by Each Reporting Person
0 shares

 

 

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o

 

 

11.

Percent of Class Represented by Amount in Row (9)
0%

 

 

12.

Type of Reporting Person (See Instructions)
CO

 

 

2


 

Item 1.

 

(a)

Name of Issuer
ViroPharma Incorporated

 

(b)

Address of Issuer’s Principal Executive Offices
397 Eagleview Boulevard
Exton, PA 19341

 

Item 2.

 

(a)

Name of Person Filing
(i)            Sanofi-Aventis

(ii)           Aventis Pharmaceuticals Inc

(iii)          Aventis Holdings Inc.

(iv)          Aventis Inc.

 

(b)

Address of Principal Business Office or, if none, Residence
(i)            174 avenue de France, 75013 Paris, France

 

(ii)           300 Somerset Corporate Boulevard, Bridgewater, New Jersey  08807

 

(iii)          3711 Kenneth Pike, Suite 200 Greenville, Delaware 19801

 

(iv)          300 Somerset Corporate Boulevard, Bridgewater, New Jersey  08807

 

(c)

Citizenship
(i)            Sanofi-Aventis : France

(ii)           Aventis Pharmaceuticals Inc : Delaware

(iii)          Aventis Holdings Inc.: Delaware

(iv)          Aventis Inc. : Pennsylvania

 

(d)

Title of Class of Securities
COMMON STOCK, $.002 PAR VALUE

 

(e)

CUSIP Number
928241108

 

Item 3.

If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 

Item 3 is not applicable.

 

(a)

o

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

 

(b)

o

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

 

(c)

o

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

 

(d)

o

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

 

(e)

o

An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

 

(f)

o

An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

 

(g)

o

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

 

(h)

o

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

 

(i)

o

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

 

(j)

o

Group, in accordance with §240.13d-1(b)(1)(ii)(J).

 

 

3


 

Item 4.

Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

 

(a)

Amount beneficially owned:   

(i) Sanofi-Aventis : 0
(ii) Aventis Pharmaceuticals Inc : 0
(iii) Aventis Holdings Inc.: 0
(iv) Aventis Inc. : 0

 

(b)

Percent of class:   

(i) Sanofi-Aventis : 0%
(ii) Aventis Pharmaceuticals Inc : 0%
(iii) Aventis Holdings Inc.: 0%
(iv) Aventis Inc. : 0%

 

(c)

Number of shares as to which the person has:

 

 

 

(i)

Sole power to vote or to direct the vote   

(i) Sanofi-Aventis : 0
(ii) Aventis Pharmaceuticals Inc : 0
(iii) Aventis Holdings Inc.: 0
(iv) Aventis Inc. : 0

 

 

(ii)

Shared power to vote or to direct the vote    

None

 

 

(iii)

Sole power to dispose or to direct the disposition of   

(i) Sanofi-Aventis : 0
(ii) Aventis Pharmaceuticals Inc : 0
(iii) Aventis Holdings Inc.: 0
(iv) Aventis Inc. : 0

 

 

(iv)

Shared power to dispose or to direct the disposition of   

None

 

Item 5.

Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   ý.

 

Item 6.

Ownership of More than Five Percent on Behalf of Another Person

 

Item 6 is not applicable.

 

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

 

Item 7 is not applicable.

 

Item 8.

Identification and Classification of Members of the Group

 

Item 8 is not applicable.

 

Item 9.

Notice of Dissolution of Group

 

Item 9 is not applicable.

 

Item 10.

Certification

 

Item 10 is not applicable.

 

 

4


 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

 

 

SANOFI-AVENTIS

 

 

Date: December 7, 2005

By:

/s/ Jean-Claude Leroy

 

 

 

 

 

 

Jean-Claude LEROY

 

Chief Financial Officer

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

 

AVENTIS PHARMACEUTICALS INC.

 

 

 

 

Date: December 7, 2005

By:

/s/ John M. Spinnato

 

 

John M. SPINNATO

 

Vice President and General Counsel
- Pharmaceutical Operations

 

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

 

AVENTIS HOLDINGS INC.

 

 

 

 

Date: December 7, 2005

By:

/s/ Joseph M. Palladino

 

 

Joseph M. PALLADINO

 

President

 

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

 

AVENTIS INC.

 

 

 

 

Date: December 7, 2005

By:

/s/ Joseph Haggerty

 

 

Joseph HAGGERTY

 

Vice President and General Counsel

 

5

 EX-1 2 a05-21260_1ex1.htm CONSENT TO JOINT FILING

EXHIBIT 1

 

DECLARATION OF CONSENT TO JOINT FILING BY SANOFI-AVENTIS, AVENTIS PHARMACEUTICALS INC, AVENTIS HOLDINGS INC AND AVENTIS INC.

 

WHEREAS, in accordance with Rule 13d-1(k) under the Securities and Exchange Act of 1934 (the “Act”), only one joint statement and any amendments thereto need to be filed whenever one or more persons are required to file such a statement or any amendments thereto pursuant to Section 13(d) of the Act with respect to the same securities, provided that said persons agree in writing that such statement or amendments thereto is filed on behalf of each of them;

 

NOW, THEREFORE, the parties hereto agree as follows:

 

Sanofi-aventis, Aventis Pharmaceuticals Inc, Aventis Holdings Inc and Aventis Inc. hereby agree, in accordance with Rule 13d-1(k) under the Act, to file a statement on Schedule 13G relating to their ownership of the Common Stock of the Issuer and do hereby further agree that said statement shall be filed on behalf of each of them.

 

 

 

SANOFI-AVENTIS .

 

 

 

 

Date: December 7, 2005

By:

/s/ Jean-Claude Leroy

 

 

Jean-Claude LEROY

 

Chief Financial Officer

 

 

 

 

 

AVENTIS PHARMACEUTICALS INC.

 

 

 

 

Date: December 7, 2005

By:

/s/ John M. Spinnato

 

 

John M. SPINNATO

 

Vice President and General Counsel
- Pharmaceutical Operations

 

 

 

 

 

AVENTIS HOLDINGS INC.

 

 

 

 

Date: December 7, 2005

By:

/s/ Joseph M. Palladino

 

 

Joseph M. PALLADINO

 

President

 

 

 

 

 

AVENTIS INC.

 

 

 

 

Date: December 7, 2005

By:

/s/ Joseph Haggerty

 

 

Joseph HAGGERTY

 

Vice President and General Counsel

 

 -----END PRIVACY-ENHANCED MESSAGE-----